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Purpose: Our purpose was to test a communication tool used in a multidisciplinary setting 
to more effectively achieve the recommended goals for glucose, blood pressure, lipids, and 
prophylactic aspirin use in a Native American population with type 2 diabetes.
Methods: One hundred randomly selected patients were included in this observational, pre-
intervention, post-intervention study design. The team began with a chart audit documenting 
hemoglobin A1c (Hgb A1c), blood pressure, cholesterol levels, and aspirin use. The intervention 
included the development of a one page form used to prompt providers to intensify therapy when 
the patient was not meeting evidence-based goals. The audit was repeated one year later.
Results: Analysis of 74 patients completing the study showed a decrease in Hgb A1C from 
8.812% pre-intervention to a mean 8.214% post-intervention (p  0.007). At the time of pre-
intervention audit, patients were already at target for blood pressure and no signiﬁ  cant further 
decrease was found. Measures of total cholesterol, triglycerides, and aspirin use showed 
improvement, but statistical signiﬁ  cance was not met.
Conclusion: The one-page multidisciplinary tool used to intensify therapy signiﬁ  cantly 
improved glucose control. More consistent interaction of the multidisciplinary team is necessary 
to reach other desired goals.
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Introduction
In recent years, the overall incidence of cardiovascular disease (CVD) has been on 
the rise among Native American populations (Howard et al 1999). It is likely that 
there are not only genetic differences resulting in varied responses to therapy in Native 
Americans, but also an issue of decreased access to optimal care. A closer examination 
by the Centers for Disease Control and Prevention reveals that 61%–64% of Native 
Americans currently have one or more risk factors that lead to the development of 
cardiovascular disease (CVD) (CDC 2000).
Diabetes has reached epidemic proportions among Native Americans. On average, 
Native Americans are 2.2 times more likely to be diagnosed with diabetes than are non-
Hispanic white cohorts of the same age. In 2003, nearly 13% of the 99,500 American 
Indians and Alaska Natives aged 20 years or older who received care from the Indian 
Health Service (IHS) in 2003 had been diagnosed with diabetes (IHS 2007). Increases 
in cardiovascular risk factors for Native Americans may be due to changes in lifestyle 
(decreases in activity level and exercise) and consumption of a more westernized diet 
with foods high in salt, fat, and cholesterol (Gilbert et al 1992). In addition, while 
complications such as retinopathy, neuropathy, and nephropathy related to diabetes 
exist and may worsen patient outcomes, the cardiovascular complications of diabetes 
(coronary heart disease, stroke, and congestive heart failure) consistently increase the Journal of Multidisciplinary Healthcare 2008:1 74
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risk of death from the disease. The IHS report that Native 
Americans with diabetes are two to three times more likely 
to develop heart disease than those without diabetes. It has 
been reported that nearly 80% of the mortality associated 
with diabetes has a cardiovascular morphology (Frey et al 
1998; NDIC 2007).
Considering the prevalence of diabetes and the negative 
outcomes that result from the disease, a patient’s entire 
health care team should consider prevention strategies to 
slow the incidence of diagnoses in all populations. When 
considering risk factors for developing CVD, hypertension 
and hyperlipidemia are less prevalent among Native 
Americans. Their existence, however, when added to existing 
hyperglycemia, continue to be major risk factors for the 
development of CVD (Frey et al 1998; Harwell et al 2001; 
Burden et al 2002).
As CVD continues to be a leading cause of death among 
Native Americans with diabetes, it is imperative that 
health care practitioners assess these major risk factors and 
develop systematic approaches for improving treatment and 
prevention efforts (Howard 1996; CDC 2000; Harwell et al 
2001). Evidence-based practice suggests that control over 
major CVD risk factors could be key to reducing morbidity 
and mortality associated with diabetes. In patients with 
limited access such as the Native American population 
studied, each health care provider who comes in contact 
with the patient should utilize a communication tool to relay 
important information about the patient’s health status to all 
essential members of the health care team in order to provide 
optimal care.
Our purpose in designing this study was to develop a tool 
that could be used by members of the multidisciplinary team 
to more effectively institute guideline-based medicine that 
optimizes the patient’s pharmacotherapy and achieves their 
health outcome goals.
Methods
The one-page tool we developed for use was named 
Treat-to-Target (see Appendix 1). The Treat-to-Target 
approach aimed at intensifying pharmacologic therapy for 
the purpose of improving the patients’ overall control of 
CVD risk factors.
The patients enrolled in Treat-to-Target were being seen 
at a local outpatient clinic that provides services primarily to 
the community members residing on the reservation. Once a 
strong need for improvement of patient care was identiﬁ  ed 
by health care providers from Creighton University and those 
employed on the reservation, our plan was implemented. 
This study used an observational, pre-intervention, 
post-intervention study design. One hundred Native 
Americans with type 2 diabetes were randomly selected from 
a diabetes center patient population. A pre-intervention chart 
review was performed which included documentation of the 
following: current hemoglobin A1c c (Hgb A1c) value, blood 
pressure, cholesterol levels, and use of preventive or prophy-
lactic aspirin. The review also recorded current medications 
and used the one-page Treat-to-Target form to recommend 
opportunities for improvement in disease state of which the 
patient was not meeting evidence-based goals. For example, 
if a chart indicated that a patient currently had an Hgb A1c 
value of 8.7% and was taking metformin 1 g twice daily and 
glipizide 10 mg twice daily, step three on the Treat-to-Target 
tool would be circled, recommending the addition of 
pioglitazone (see Appendix 1). The Treat-to-Target sheet 
was placed in the patient’s medical chart for the prescriber 
to see at the next patient visit.
Of note, the Treat-to-Target intervention used a low-
density lipoprotein (LDL) goal of 100 to ensure at least 
the recommended goal for patients with diabetes was met. 
No recommendations were made for further reduction after 
that goal was met.
Immediately following the ﬁ  rst audit, the intervention 
was performed. It consisted of an educational inservice to the 
medical and nursing staff at the diabetes clinic. The inservice 
explained the development of the Treat-to-Target approach 
to intensify drug therapy to reach speciﬁ  c goals and cited 
the source of the recommendations as those of the American 
Diabetes Association (ADA) (2008). The presentation to 
the medical staff delineated the outcomes evidence behind 
these guidelines that led to the target goals, and explained 
how this sheet could be used in the current clinic structure 
to aid in achieving target goals for glucose, blood pressure, 
lipids, and aspirin use.
Approximately 13 months later, a post-intervention 
chart review was repeated in which the patients served as 
their own controls. The same data were collected as before: 
current Hgb A1C value, blood pressure, LDL cholesterol 
value, and use of aspirin. A paired t-test comparison was 
made for each pre-post data set for the Hgb A1c values, LDL 
cholesterol values, and aspirin use data, in which p  0.05 
was considered signiﬁ  cant.
Results
A total of 73 participants had complete data. Due to 
nonnormal distributions, nonparametric statistics were used. 
For continuous data, the Wilcoxon signed-ranks test was Journal of Multidisciplinary Healthcare 2008:1 75
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used, while the McNemar test was used for nominal data. 
A Bonferroni adjustment adjusted α = 0.007 to reduce the 
probability of type 1 error from multiple analyses of the 
same data.
Data about each collected parameter is summarized in 
Table 1. Hgb A1c values decreased from a mean 8.812% 
pre-intervention to a mean 8.214% post-intervention 
(p  0.007). Patients were meeting the ADA’s goals 
for systolic and diastolic blood pressure before the 
Treat-to-Target tool was initiated with a pre-intervention 
mean of 128.1/72.68 mm Hg. Slight reductions in both 
systolic and diastolic levels were found post-intervention 
(though not statistically signiﬁ  cant) with mean blood pressure 
being 127.11/71.11 (p = 0.47). Neither total cholesterol nor 
triglyceride levels decreased signiﬁ  cantly, though reductions 
were noted in both. Insufﬁ  cient LDL cholesterol values were 
drawn for analysis. Using the McNemar test to evaluate aspi-
rin use pre-and post-intervention, nonsigniﬁ  cant increases in 
the number of patients on aspirin were found (p = 0.503).
Discussion
Current practice in the treatment of diabetes and cardiovascular 
disease does not offer a standard tool for adjusting 
pharmacotherapy. There are many considerations that go into 
making alterations in patient medications and our study has 
provided a tool that could provide any health care provider 
the ability to make consistent evidence-based decisions each 
time the patient was seen. We believe this would likely lead 
to improved patient outcomes.
The environment this tool was piloted in was a 
rural, Native American outpatient clinic in which a 
multidisciplinary approach to treating patients was used 
frequently. Interventions made by all members of the 
healthcare team were expected to provide the patient 
with optimal care. The ability to make recommendations 
directly to the provider through a previous chart review 
was appreciated by the providers as they were able to have 
maximal impact on patients they saw in clinic despite short 
appointment times.
Using a chart review process and incorporation of the 
Treat-to-Target approach by a multidisciplinary team was 
a successful method to reduce Hgb A1c values and helped 
to align patients closer to other goals outlined in the ADA 
standards for treating diabetes. The results, however, indicate 
that a more intensive effort is needed in the areas of achieving 
cholesterol and aspirin use goals.
Cholesterol monitoring and assessment of adherence 
to daily aspirin was not performed at frequent intervals 
to ensure goals were met. More frequent monitoring may 
have been accomplished through improved incorporation 
of other members of a multidisciplinary team that may have 
more access to the patient. Our study used pharmacists only 
to review the patient’s chart and make recommendations. 
However, if each provider active in caring for the patient 
was prompted to utilize the algorithm developed each time 
the patient was seen, improved compliance to medications, 
laboratory draws, and more frequent evaluations of those 
results may have resulted in more positive outcomes.
As patients are multifaceted individuals, so are their 
disease states. There are many modiﬁ  cations necessary in 
addition to drug therapy that will affect their ability to obtain 
goals. Exploration into the role that health care professionals 
on the multidisciplinary team could play in these efforts 
would also be beneficial in developing a more holistic 
approach to managing the disease. An example of this could 
include discussion of lifestyle modiﬁ  cations recommended 
by the ADA. As westernization of Native American diets 
has been cited as a contributing factor to the development of 
diabetes, ensuring that patients meet with providers trained in 
dietary counseling could be essential to improving outcomes. 
Non-pharmacologic methods of reducing risk of developing 
CVD were not included on the Treat-to-Target tool, and 
data comparing differences in patients’ knowledge and use 
of those methods was not collected.
Table 1 Results from Treat-To-Target
N Pre-intervention Pre-intervention mean N Post-intervention Post-intervention mean p value
Hgb A1c 73 8.812% 70 8.214% 0.007*
Systolic blood pressure 72 128 72 127 0.47
Diastolic blood pressure 72 72 72 71 0.096
Total cholesterol 72 199 67 192 0.179
Triglycerides 71 266 66 255 0.236
Abbreviation: Hemoglobin, A1cHgb A1c.
Note: *statistical signiﬁ  cance.Journal of Multidisciplinary Healthcare 2008:1 76
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Another limitation that may have affected the results of 
our study is the lack of knowledge of the patients’ medication 
history unrelated to those treating their diabetes, hypertension, 
hypercholesterolemia, or aspirin. It is not known if patients 
were on other antiplatelet or anticoagulant agents that 
may have limited aspirin use in an attempt to lower risk of 
bleeding. It is also not known if patients may have been taking 
a medication that may have increased their risk for developing 
metabolic syndrome (atypical antipsychotics).
Future efforts must also address guidelines regarding 
recommended annual measurements necessary to prevent or 
monitor diabetes related complications such as nephropathy, 
neuropathy, retinopathy, and others. Cardiovascular disease 
was the only outcome the study aimed at preventing. Patients 
with diabetes, however, should have all aspects of their health 
considered when seen by their health care professionals and 
incorporating these guidelines into the tool would be beneﬁ  cial 
in preventing those negative outcomes from occurring.
Differences in the patient population could have affected 
compliance with taking the medications recommended. 
Baseline demographics were not gathered in this study. Cultural 
competency training for all providers may impact patient interest 
and compliance with the regimens and should be recommended 
in this population. This could be extrapolated to other settings 
with the diversity that exists in our communities today.
Despite these limitations, the signiﬁ  cant improvement in 
glycemia seen with our one-page communication tool used to 
review the patient’s medical chart validates the importance 
of working with a multidisciplinary team to achieve the 
common goal of optimal patient care. As only pharmacists 
and primary care providers used the Treat-to-Target tool in 
our study, we have also demonstrated the need to involve 
the entire team, including all health care professionals the 
patients see, to achieve an even greater impact on reducing 
progression to CVD. We believe our study demonstrates 
the fact that if it became the responsibility of not only the 
primary care provider, but the mission of the entire patient 
care team in this setting, the epidemic of diabetes could be 
slowed.
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Appendix 1
Treat-to-Target Diabetes Review
Circle recommended action
Blood glucose control Recommended level of control HbA1c <7.0%
Obese type 2
Step one Metformin 500 mg po BID      Optimal dose: 1 gm
BID; do not use with Scr >1.4 or ClCr <40
Step two Pioglitazone 15 mg po QD      No adverse 
effects on LDL cholesterol; optimal dose: 45 mg QD; 
LFTs: baseline, every other month for the ﬁ  rst year, 
periodically thereafter
Step three Glyburide or glipizide  5 mg  Optimal dose: 10 mg QD; glipizide 
should be dosed 5 mg BID if not XL
Obese type 2 receiving >100 units of insulin/day:
Add metformin or pioglitazone and decrease total daily dose of insulin by 10%
Add enteric-coated aspirin (75–162 mg/day) for anyone >30 years with
A family history of heart disease Cigarette smoking
Hypertension Obesity (>120% desirable weight)
Albuminuria (micro or macro)
Lipids: 
Cholesterol >200 mg/dL
Triglycerides >200 mg/dL
HDL <45 mg/dL (men) and <55 mg/dL (women)
LDL >100 mg/dL
People with aspirin allergy, bleeding tendency, anticoagulant therapy, recent gastrointestinal bleeding, and clinically active hepatic disease are not 
candidates for aspirin therapy
Abbreviations: ACE, angiotensin-converting enzyme; ALT, alanine aminotransferase; BID, twice daily; Hgb A1c, hemoglobin A1c; HCTZ, hydrochlorothiazide; HDL, high-density 
lipoprotein; LDL, low-density lipoprotein; LFT, ; QD, once daily; TID, three times daily. Copyright © 2006. Michael S Monaghan, All Rights Reserved.
Lipid control
LDL Recommended level of control <100 mg/dL
Step one Statin
Step two Statin + fenoﬁ   brate     Micronized
fenoﬁ  brate 200 mg QD with main meal; LFTs: 
baseline, every 3 months for the ﬁ  rst year;
if ALT >100 IU/L, DC therapy
Triglycerides Recommended level of control <150 mg/dL
Step one Gemﬁ  brozil or fenoﬁ  brate Fenoﬁ  brate: 67 mg QD with meal; max 67 mg
TID with meals
Blood pressure control    Recommended level of control 130/80 mm Hg
Step one ACE inhibitor Severe renal impairment – fosinopril is preferred
Step two HCTZ 25 mg po QD
Step three Calcium channel blocker Diltiazem and verapamil are preferred